Receptor occupancy (RO) studies have long been used to demonstrate target engagement of therapeutic antibodies. Today, many programs rely on RO data to inform dose selection, pharmacodynamic interpretation, biomarker strategy, and mechanism-of-action assessments. Bispecific antibodies, T-cell engagers, antibody-drug conjugates (ADCs), and other next-generation therapies have expanded both the opportunities and complexities associated with receptor occupancy assessments [1].
The Operational Side of Receptor Occupancy
RO studies can be particularly sensitive to what happens between sample collection and sample analysis. Receptors may internalize, shed, recycle, or change expression during handling and transport, creating the potential for measured occupancy to diverge from the biological state present in the patient at the time of collection.
In multicenter studies, differences in collection procedures, processing timelines, stabilization approaches, and shipping conditions can introduce variability across sites. As a result, sample management is often as important to study success as assay performance itself.
For many programs, critical decisions made during study design, such as sample stabilization strategies, processing windows, logistics planning, and site training, have a direct impact on data quality and interpretation. Equally important is the design of the RO assay itself. The most robust RO studies combine a rigorous sample management approach with assay strategies that accurately capture the biology of the target and therapeutic.
The Importance of Cellular Context
High-parameter flow cytometry, when supported by properly designed assays and analytical strategies, enables occupancy assessments within highly defined immune populations, including rare subsets that may represent only a small fraction of the total sample. This level of resolution allows drug developers to examine target engagement within the cell populations most relevant to therapeutic activity rather than relying solely on measurements across broader cell populations that may mask important biological differences [2].
In some programs, however, the key receptor-expressing cells are not primarily found in circulation. The biologically relevant target population may reside within tumors, inflamed tissues, lymphoid organs, or other tissue compartments [3]. In these situations, peripheral blood measurements may provide only a partial view of target engagement.
Study teams must therefore determine whether peripheral blood is an appropriate surrogate for target engagement at the site of action or whether additional matrices are required. The answer depends on the biology of the target, the mechanism of the therapeutic, and the feasibility of sample collection within the clinical study.
Validation is especially challenging when the biologically relevant target population is not readily accessible in clinical studies. While tissue-based assessments may offer a more direct view of target engagement at the site of action, limitations related to sample acquisition, tissue processing, cellular recovery, and assay standardization can make such measurements difficult to implement routinely.
As a result, peripheral blood is frequently used as a practical surrogate compartment for receptor occupancy assessments. Blood-based measurements provide valuable evidence of target engagement, particularly when supported by preclinical, translational, or mechanistic data demonstrating a relationship between circulating and tissue-resident target populations. The greatest insight is often gained when RO data are interpreted alongside complementary pharmacodynamic, biomarker, and mechanistic endpoints, providing a more comprehensive understanding of biological activity.
Receptor Trafficking Implications
In practice, receptor binding is only one part of a dynamic biological process. Receptor expression and availability can be influenced by trafficking processes such as internalization, recycling, and shedding, which may occur naturally, be altered following target engagement, or continue ex vivo during sample handling [4]. These dynamics can affect both biological activity and the interpretation of receptor occupancy measurements, particularly when occupancy data are used to support dose selection and pharmacodynamic conclusions.
The biological significance of receptor occupancy can vary considerably depending on what happens after binding. For some therapeutics, sustained receptor engagement at the cell surface may be associated with pharmacologic activity. For others, receptor internalization may be an expected part of the mechanism, driving downstream signaling, receptor depletion, or payload delivery. In these settings, occupancy alone may not fully explain therapeutic activity When assay design permits, assessment of both occupancy and total receptor can provide valuable context for interpreting the biological significance of target engagement. Achieving this, however, often depends on careful scientific considerations that are not always straightforward, particularly for novel targets or complex therapeutic modalities. For many programs, understanding receptor trafficking and turnover provides insights that cannot be captured through occupancy measurements alone. Distinguishing between surface-bound receptors, internalized receptor-drug complexes, and shed receptor populations can help characterize mechanism of action, explain differences in patient response, and support a more complete understanding of target biology.
The Reality of RO Assay Development
Not every target supports a classical receptor occupancy strategy. While traditional RO approaches rely on measuring free, bound, and total receptor populations, the reagents needed to support those measurements are not always available for novel targets, engineered receptors, or complex therapeutic constructs.
When suitable non-competing antibodies or anti-idiotype reagents are unavailable, the assay strategy may need to be reconsidered. Alternative approaches such as receptor saturation experiments or secondary detection strategies can sometimes provide a path forward, but each introduces its own scientific and technical considerations.
Additionally, therapeutic binding may alter epitope accessibility, promote receptor clustering, or trigger rapid internalization, making traditional occupancy measurements difficult to interpret. In these situations, the goal is often not to force a conventional RO design, but to identify the approach that best answers the underlying biological question.
Complexity can also arise when target expression is low or highly heterogeneous across cell populations, requiring assay strategies capable of reliably characterizing occupancy at the limits of detection.
For some programs, a traditional free, bound, and total receptor paradigm remains appropriate. For others, demonstrating target engagement may require a combination of receptor occupancy measurements, receptor expression data, and complementary pharmacodynamic endpoints.
New Modalities, New Expectations
As more bispecific programs enter the clinic, expectations for receptor occupancy studies continue to evolve. These therapies, along with multispecific antibodies, ADCs, and other immune-engaging modalities, frequently target low-abundance receptors, drive complex cellular interactions, and operate through mechanisms that extend beyond simple receptor binding.
Sponsors are increasingly looking for data that connects target engagement to biological consequences. Questions surrounding receptor trafficking, cellular activation, population-specific engagement, and downstream pharmacology have become routine components of development programs.
For many programs, receptor occupancy is now a critical link between exposure and pharmacodynamic response. The goal is not only to demonstrate that a therapeutic engages its target, but also to understand how that engagement drives biological activity.
References:
[1] Shui L, Wu D, Yang K, Sun C, Li Q, Yin R. Bispecific antibodies: unleashing a new era in oncology treatment. Mol Cancer. 2025 Aug 4;24(1):212. doi: 10.1186/s12943-025-02390-y. PMID: 40760704; PMCID: PMC12320366.
[2] Hilt E, Sun YS, McCloskey TW, et al. Best practices for optimization and validation of flow cytometry-based receptor occupancy assays. Cytometry. 2021; 100:63–71.
[3] Jha, D., Garma, H., Lear, S., Schroeder, A., Onabajo, O., Fuh, F., O'Gorman, W. E., Taylor, M. D., McBride, J., Neighbors, M., & Mehandru, S. (2026). Establishing a flow cytometry-based tissue receptor occupancy assay for an anti-oncostatin M receptor beta subunit therapeutic candidate in inflammatory bowel disease. Cytometry Part B: Clinical Cytometry, 110(4), 274–287.
[4] Hammood M, Craig AW, Leyton JV. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals (Basel). 2021 Jul 15;14(7):674. doi: 10.3390/ph14070674. PMID: 34358100; PMCID: PMC8308841.
